Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Short Interest Up 113.1% in March

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 745,300 shares, an increase of 113.1% from the February 28th total of 349,800 shares. Approximately 7.5% of the company’s stock are sold short. Based on an average daily volume of 7,170,000 shares, the short-interest ratio is currently 0.1 days.

Petros Pharmaceuticals Stock Down 22.5 %

NASDAQ:PTPI traded down $0.03 during trading hours on Friday, hitting $0.09. The company’s stock had a trading volume of 19,121,165 shares, compared to its average volume of 9,052,678. The stock has a fifty day moving average of $0.18 and a 200-day moving average of $0.28. The stock has a market capitalization of $973,434.00, a P/E ratio of -0.02 and a beta of 2.04. Petros Pharmaceuticals has a 52-week low of $0.05 and a 52-week high of $1.48. The company has a current ratio of 0.85, a quick ratio of 0.74 and a debt-to-equity ratio of 1.58.

Petros Pharmaceuticals Company Profile

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).